Shots:

• McGill to receive $350-000 up front- $10.5M as development and regulatory milestone & is also eligible for ~$30M as a commercial milestone. Clarus will develop and commercialize McGill’s technology targeted the conditions associated with CoQ10 deficiencies
• The collaboration will accelerate the development of potential treatments for rare- endocrine- metabolic- and neurological conditions associated with primary and secondary ubiquinone deficiencies belong to a broader class of mitochondrial diseases
• The collaboration also broadens Clarus’ focus beyond androgen-based medicines to a metabolic therapy for CoQ10 deficiencies

  | Ref: Globe Newswire | Image: PR Newswire